Co-Managing the Diabetic Patient

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

Mark Dunbar, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc.

Paul Chous, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch & Lomb Incorporated; CooperVision; Freedom Meditech, Inc.; Regeneron Pharmaceuticals, Inc.; and ZeaVision, LLC and Grant/Research Support: ZeaVision, LLC

Leo Semes, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Optovue, Inc.; and Regeneron Pharmaceuticals, Inc. and Stock/Shareholder: HPO

Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.

Disclosure Attestation Each of the contributing faculty listed above has attested to the following:

1.       That the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity;

2.       That practice recommendations given relevant to the companies with whom he or she has relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and

3.       That all reasonable clinical alternatives will be discussed when making practice recommendations.